Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Low NSAID Knowledge, Satisfaction In Consumer Pain Medication Survey

This article was originally published in The Pink Sheet Daily

Executive Summary

While 60% of consumers use an OTC medicine for pain, nearly a third are not satisfied with the results, according to Kelton Global's research on consumer understanding of pain medication. Nearly half of consumers are not familiar with the term NSAIDs or with FDA recommendations on using the products.

You may also be interested in...



‘Double Check’ Acetaminophen Message Reaches Walmart Pharmacies

The Acetaminophen Awareness Coalition says its efforts are “validated” by a study finding public awareness campaigns are critical to prevent accidental overdose of OTC drug ingredients. AAC will provide educational materials to 4,600 Walmart stores by the end of 2015, says CHPA.

Coty Continues Licensing Spree With Etro; CEO Nabi Shares Prestige Fragrance Vision

At CAGNY 2024, CEO Sue Nabi discussed Coty’s prestige fragrance strategy, including growing emphasis on ultra-premium offerings and continued focus on fashion-driven licenses, the same day the company announced a long-term fragrance licensing deal with Italian brand Etro.

China Drags On Shiseido, Kao In 2023; Sally Beauty Partners With Black Hair Experience; Beauty News

Shiseido and Kao report China and travel retail were significant headwinds in 2023, though both expect smoother sailing ahead. More beauty news in brief.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079438

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel